1.5m2, 60mg twice daily.

3 trials

Sponsors

Kanagawa Cancer Center, Fukuoka Tumor Research(FUTURE)

Conditions

advanced colorectal cancermetastatic colorectal cancer

Unknown Phase

A phase I/II study of Cetuximab combined with irinotecan and S-1 as first line therapy in metastatic colorectal cancer patients with KRAS wild type

Active, not recruitingJPRN-UMIN000004403

Kanagawa Cancer Centeradvanced colorectal cancer

Start: 2010-11-01Target: 40Updated: 2026-06-29

A phase II study of Panitumumab combined with Irinotecan and S-1 as second line therapy in metastatic colorectal cancer patients with KRAS wild type

RecruitingJPRN-UMIN000004697

Kanagawa Cancer Centeradvanced colorectal cancer

Start: 2010-12-01Target: 30Updated: 2026-06-29

A phase I/II study of combination therapy with S-1/ CPT-11 plus Panitumumab as second line therapy in metastatic colorectal cancer patients with KRAS wild type

Active, not recruitingJPRN-UMIN000005218

Fukuoka Tumor Research(FUTURE)metastatic colorectal cancer

Start: 2011-03-01Target: 35Updated: 2026-06-29